$DWTX News

Dogwood Announces $5 Million Private Placement with CK Life Sciences Int’l., (Holdings) Inc.

Dogwood Therapeutics Enters Into Securities Subscription Agreement For $5 Investment From CK Life Sciences’ Subsidiary

Dogwood to Participate in the 2026 Maxim Growth Summit

Dogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b Trial

Dogwood Therapeutics, Inc. (DWTX) Discusses Halneuron and Pipeline Advances for Chemotherapy-Induced Neuropathic Pain Transcript

Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026

Dogwood Therapeutics Announces Second Quarter 2026 Financial Results

Dogwood Therapeutics Q2 EPS $(0.34) Misses $(0.14) Estimate

Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026

Dogwood Therapeutics Admits First 200 Participants In Its Current HAL-CINP Phase 2b Study To Evaluate Efficacy, Safety Of Halneuron

Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board

Dogwood Therapeutics, Inc. (DWTX) Shareholder/Analyst Call Prepared Remarks Transcript

HC Wainwright & Co. Reiterates Buy on Dogwood Therapeutics, Maintains $12 Price Target

Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study

Dogwood Therapeutics Starts New Halneuron Hemotherapy Induced Neuropathic Pain Phase 2b Extension Trial

Dogwood Therapeutics (NASDAQ:DWTX) Beats EPS Estimates in Q1 2026, Phase 2b Trial on Track

Dogwood Therapeutics Announces First Quarter 2026 Financial Results

Dogwood Therapeutics Q1 EPS $(0.15), Inline

Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026

HC Wainwright & Co. Reiterates Buy on Dogwood Therapeutics, Maintains $12 Price Target